Table 1.
Summary of optimized β values for Q.Clear in various PET imaging settings
| Publication | Tracer | Application | Optimal β value | Scanner type | Study type |
|---|---|---|---|---|---|
| Teoh et al. 2015 [22] | 18F-FDG | Pulmonary nodules | 400 | Discovery 690 PET/CT | Phantom and clinical |
| Howard et al. 2017 [39] | 18F-FDG | Small pulmonary nodules (mean diameter of 8 mm) | 150 | Discovery IQ PET/CT | Clinical |
| Wangerin et al. 2017 [40] | 18F-FDG | Synthetic spherical lesions in liver and lung regions | 450 (liver); 250 (lung) | Discovery 690 PET/CT | Clinical |
| Rowley et al. 2017 [41] | 90Y | Post- selective internal radiotherapy (SIRT) imaging for the treatment of liver malignancies | 4,000 | Discovery 710 PET/CT | Phantom and clinical |
| O’Doherty et al. 2017 [42] | 13N-NH3 | Quantitative myocardial blood flow (MBF) imaging | 300 | Discovery 710 PET/CT | Clinical |
| Reynes-Llompart et al. 2018 [27] | 18F-FDG | Brain acquisitions (neuro-oncologic) and torso acquisitions (oncologic whole body acquisition) | 200 (brain); 350 (torso) | Discovery IQ PET/CT | Phantom and clinical |
| Teoh et al. 2018 [43] | 18F-fluciclovine | Prostate cancer | 300 | Discovery 710 PET/CT | Clinical |
| Bjöersdorff et al. 2019 [44] | 18F-fluorocholine | Prostate cancer | 400–550 | Discovery MI PET/CT | Clinical |
| Miwa et al. 2020 [45] | 18F-FDG | Sub-centimeter tumor lesions | 200 | Discovery MI PET/CT | Phantom |
| Lindstrom et al. 2020 [46] | 18F-flutemetamol | Alzheimer’s disease (AD) with Aβ pathology | 300 | Discovery MI PET/CT | Clinical |
| Texte et al. 2020 [47] | 18F-FMISO/18F-FAZA | Hypoxia imaging of non-small cell lung carcinoma (NSCLC) | 350 | Discovery 710 PET/CT | Phantom and clinical |
| Seo et al. 2020 [48] | 68 Ga-citrate |
Prostate cancer with castration-resistant disease |
500 | SIGNA PET/MRI | Phantom and clinical |
| Yoshii et al. 2020 [34] | 18F-NaF | Bone metastases | 400 | Discovery MI PET/CT | Phantom and clinical |
| Baratto et al. 2020 [49] | 68 Ga-RM2/68 Ga-PSMA | Prostate cancer | 400–600 | SIGNA PET/MRI | Clinical |
| Witkowska-Patena et al. 2020 [50] | 18F-PSMA-1007 | Prostate cancer | 350 | Discovery 710 PET/CT | Clinical |
| Chicheportiche et al. 2021 [33] | 68 Ga-DOTA | Neuroendocrine tumors | 1,300–1,600 | Discovery MI PET/CT | Phantom and clinical |
| Kirchner et al. 2021 [51] | 89Zr-immunoPET tracer | 89Zr-immuno PET imaging | 3,600 | Discovery 710 PET/CT | Clinical |
| Usmani et al. 2021 [52] | 18F-NaF | Skeletal staging in obese patients | 600 | Discovery 710 PET/CT | Phantom and clinical |
| Rijnsdorp et al. 2021[53] | 68 Ga-PSMA | Prostate cancer | 600 | Discovery 710 PET/CT | Clinical |
| Wagatsuma et al., 2022 [25] | 11C-PiB/18F-FDG | Alzheimer’s disease (AD) with Aβ pathology | 300 (11C-PiB); 200 (18F-FDG) | Discovery 710 PET/CT | Phantom and clinical |
| Ribeiro et al. 2022 [54] | 11C-PHNO | Dynamic brain PET | 100–200 | SIGNA PET/MRI | Clinical |
| Tian et al. 2022 [55] | 18F-FDG | General tumor PET/MRI imaging | 400 | SIGNA PET/MRI | Phantom and clinical |
| Ruan et al. 2023 [36] | 68 Ga-FAPI | Lesions with obviously high FAPI uptake | 350 | SIGNA PET/MRI | Clinical |
| Margail et al. 2023 [56] | 68 Ga-PSMA-11 |
Biochemical recurrence of prostate cancer |
400–600 | Discovery 710 PET/CT and Discovery MI PET/CT | Clinical |
| Young et al. 2023 [57] | 15O-H2O | Dynamic PET for quantitative cerebral blood flow (CBF) measurements | 300 | Discovery MI PET/CT | Clinical |
| Sadeghi et al. 2023 [58] | 18F-FDG | Rectal cancer detection using BGO-based PET | 500 (large lesions); 300(small lesions) | Discovery IQ PET/CT | Phantom and clinical |
| Fukuda et al. 2024 [59] | 18F-flutemetamol | Amyloid PET imaging without PSF correction | 300 | Discovery MI PET/CT | Phantom and clinical |
| Fooladi et al. 2024 [37] | 68 Ga-PSMA | Robustness of radiomics features in PSMA-PET images | 300–500 | Discovery IQ PET/CT | Phantom and clinical |
| Wagatsuma et al. 2024 [60] | 18F-flutemetamol | Amyloid PET imaging without PSF correction | 600 | Discovery MI PET/CT | Phantom and clinical |
| Calatayud-Jordán et al. 2024 [61] | 90Y | 90Y PET/MR imaging after SIRT | 4,000 (high image quality); 1,500–2,000 (high quantitation) | SIGNA PET/MRI | Phantom |
| Di Franco et al.\, 2024 [62] | 68 Ga-DOTANOC | Neuroendocrine tumors | 1,300–1,600 | Discovery MI PET/CT | Clinical |
| Bonney et al. 2025 [63] | 89Zr | Optimizing phantom studies for quantitative imaging | 1,500 | Discovery 710 PET/CT | Phantom |